Skip to main content
MedPathMedPath Home
Clinical Trials/RPCEC00000393
RPCEC00000393
Not yet recruiting
Phase 2

Evaluation of the effect and safety terapeutic of Jusvinza in severe patients with COVID-19

Center for Genetic Engineering and Biotechnology (CIGB), Havana0 sites108 target enrollmentOctober 26, 2021
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAcute Respiratory Distress by Covid-19COVID-19SARS-CoV-2Coronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusSevere Acute Respiratory SyndromeRespiratory Tract Disease

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Acute Respiratory Distress by Covid-19
Sponsor
Center for Genetic Engineering and Biotechnology (CIGB), Havana
Enrollment
108
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 26, 2021
End Date
May 15, 2022
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Center for Genetic Engineering and Biotechnology (CIGB), Havana

Eligibility Criteria

Inclusion Criteria

  • •1\. Age \= 19\.
  • •2\. Virologial diagnosis by RT\-PCR to SARS\-Cov\-2\.
  • •3\. Patients with serious status.
  • •4\. Willingness of the patient through informed consent

Exclusion Criteria

  • •1\. Patients with kidney disease on hemodialysis.
  • •2\. Known hypersensitivity to any of the components of the formulations under study
  • •3\. Pregnancy or breastfeeding.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 2
VALERGEN-combination of routes- Asthma-Adults-Phase IIAsthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental Illness
RPCEC00000298ational Center of Bioproducts (BioCen)180
Recruiting
Phase 1
Itolizumab (T1h) combined with insulin in patients with Type I Diabetes MellitusType 1 diabetes mellitusDiabetes Mellitus, Type 1Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases
RPCEC00000225Center of Molecular Immunology (CIM)40
Not yet recruiting
Phase 1
euroEPO – Type 2 Spinocerebellar Ataxia Phase I-IIType 2 Spinocerebellar Ataxia
RPCEC00000187Center of Molecular Immunology (CIM), CIMAB34
Completed
Not Applicable
Evaulation of the clinical efficacy and safety of the combined administration of Imidafenacin and Tamsulosin in BPH patients (in which OAB symptoms remain) who did not respond to alpha-1 blocker monotherapy.Overactive bladder
JPRN-UMIN000005012Department of Urology, University of Yamanashi, School of Medicine300
Active, not recruiting
Phase 1
Evaluation of the safety and efficacy of the treatment of chronic wounds in diabetic foot syndrome with the use of autologous stem cells isolated from adipose tissue - within the project: Therapeutic potential of adipose-derived stem cells, proven in clinical trials and examined in vitro - rationale for banking of well characterized cells”Diabetic foot ulcerMedDRA version: 20.0 Level: LLT Classification code 10012664 Term: Diabetic foot ulcer System Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
EUCTR2016-004109-15-PLMedical University of Warsaw50